Classification: Lipid Regulating Drug (Statins)
Action: Inhibits HMG-COA reductase enzyme, which, reduces cholesterol synthesis; this enzyme is needed for cholesterol production.
Indication: To reduce low-density lipoprotein (LDL) cholesterol, apolipoprotein beta, and triglycerides. To increase hihg density lipoprotein (HDL) cholesterol in the treatment of hyperlipidaemias, including hypercholesterolemias and combined hyperlipidaemia. Also used as adjunct therapy in patients with homozygous familial hypercholesterolaemias and as prophylaxis to hypercholesterolaemic patients with ischemic heart disease. Coronary heart disease.
Adverse Reactions: Abdominal pain, constipation, flatulence. Nausea, acid vomiting, diarrhea, dyspepsia. Headache, insomnia, rashes. Pruritus, diziness, muscle cramps.
- Assess nutrition
- Monitor creatine phosphokinase levels, serum cholesterol
- Monitor for triglycerides, cholesterol baseline and throughout treatment
- Assess liver function tests prior to therapy and periodically thereafter
- Eveluate therapeutic response and adverse reactions on a regular basis
- Assess knowledge and teach patient proper use (as adjunct to diet and exercise program), possible side effects, appropriate interventions, and adverse symptoms to report
- Give 30 minutes before AM and PM meals
- Instruct patient to take drug with the evening meal because taking this enhances absorption and increases cholesterol biosynthesis
- Teach patient about proper dietary management of cholesterol and triglycerides. When appropriate, recommend weight control, exercise, and smoking cessation programs.
- Tell patient to notify physician if adverse reactions occur, particularly muscle aches and pains.
- Inform physician if patient is pregnant
- Decreased cholesterol levels, serum triglycerides and improved ratio with HDLs